PARP Inhibitors in Prostate Cancer–the Preclinical Rationale and Current Clinical Development
Virtanen, V.; Paunu, K.; Ahlskog, J.K.; Varnai, R.; Sipeky, C.; Sundvall, M. PARP Inhibitors in Prostate Cancer–the Preclinical Rationale and Current Clinical Development. Genes 2019, 10, 565. https://doi.org/10.3390/genes10080565
Virtanen V, Paunu K, Ahlskog JK, Varnai R, Sipeky C, Sundvall M. PARP Inhibitors in Prostate Cancer–the Preclinical Rationale and Current Clinical Development. Genes. 2019; 10(8):565. https://doi.org/10.3390/genes10080565
Chicago/Turabian StyleVirtanen, Verneri, Kreetta Paunu, Johanna K. Ahlskog, Reka Varnai, Csilla Sipeky, and Maria Sundvall. 2019. "PARP Inhibitors in Prostate Cancer–the Preclinical Rationale and Current Clinical Development" Genes 10, no. 8: 565. https://doi.org/10.3390/genes10080565